REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
REGENERON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$782.04−8.70 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $82.90B
- P/E (TTM)
- 19.3
- Dividend yield
- –
Regeneron Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $80.51B | $197.05M |
| Enterprise Value | $74.51B | $106.56M |
| PE Ratio | 19.34 | 20.52 |
| PS Ratio | 5.18 | 3.93 |
| PB Ratio | 2.54 | 2.14 |
| P/TBV Ratio | 2.65 | 2.46 |
| P/FCF Ratio | 21.41 | 18.25 |
| P/OCF Ratio | 17.20 | 13.78 |
Enterprise value
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 4.80 | 2.69 |
| EV / EBITDA | 17.04 | 14.86 |
| EV / EBIT | 19.39 | 19.00 |
| EV / FCF | 19.81 | 21.02 |
Income (trailing twelve months)
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $15.53B | $57.94M |
| Operating Income | $3.84B | -$21.44M |
| Pretax Income | $5.17B | -$14.45M |
| Net Income | $4.33B | -$22.46M |
| EBITDA | $4.37B | -$16.91M |
| EPS (Diluted) | $40.44 | -$0.83 |
Margins
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | 24.7% | -44.5% |
| Pretax Margin | 33.3% | -13.0% |
| Profit Margin | 27.9% | -39.2% |
| EBITDA Margin | 28.1% | -31.3% |
| FCF Margin | 24.2% | -8.85% |
Returns
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | 14.0% | -53.1% |
| Return on Assets (ROA) | 10.8% | -41.0% |
| Return on Invested Capital (ROIC) | 12.8% | -32.0% |
| Return on Capital Employed (ROCE) | 10.6% | -37.8% |
Growth
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 9.29% | 6.01% |
| Net Income Growth (YoY) | -2.91% | -37.7% |
| EPS Growth (YoY) | 1.86% | -29.2% |
| FCF Growth (YoY) | -2.42% | 2.34% |
| Revenue Growth (3Y CAGR) | 5.62% | 2.25% |
| Revenue Growth (5Y CAGR) | 11.0% | 6.42% |
| EPS Growth (3Y CAGR) | 2.77% | -0.17% |
| EPS Growth (5Y CAGR) | 6.33% | 3.77% |
Balance sheet
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $7.99B | $62.42M |
| Total Debt | $1.99B | $120.13M |
| Net Cash (Debt) | $6.01B | $15.68M |
| Net Cash Per Share | $58.36 | $0.65 |
| Equity (Book Value) | $31.71B | $48.79M |
| Book Value Per Share | $308.01 | $1.36 |
| Tangible Book Value | $30.40B | $23.06M |
| Working Capital | $12.92B | $75.77M |
Financial position
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 3.34 | 3.30 |
| Quick Ratio | 2.63 | 2.39 |
| Debt / Equity | 0.06 | 0.51 |
| Debt / EBITDA | 0.45 | 3.35 |
| Debt / FCF | 0.53 | 5.05 |
| Net Debt / EBITDA | -1.37 | 2.22 |
| Interest Coverage | 69.37 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $4.68B | -$12.35M |
| Capital Expenditures | -$920.90M | -$1.06M |
| Free Cash Flow | $3.76B | -$20.28M |
| FCF Per Share | $36.52 | -$0.41 |
Efficiency
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.39 | 0.38 |
| Revenue Per Employee | $1.01M | $398.96K |
| Profits Per Employee | $280.90K | -$732.08K |
| Employee Count | 15,410 | 73 |
Dividends and yields
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 5.38% | -21.2% |
| FCF Yield | 4.67% | -7.64% |
| Buyback Yield | 3.16% | -0.58% |
| Shareholder Yield | 3.16% | 0.00% |
| Payout Ratio | 8.74% | 47.7% |
| FCF Payout Ratio | 10.1% | 51.6% |
Shares
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 102,955,000 | 59,128,900 |
| Shares Change (YoY) | -4.67% | 11.1% |
| Float | 99,071,100 | 48,744,500 |
| Shares Held by Insiders | 3.77% | 11.8% |
| Shares Held by Institutions | 89.0% | 59.4% |
Taxes
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $837.30M | $91.50K |
| Effective Tax Rate | 16.2% | 20.6% |
Scores
| Measure | Regeneron Pharmaceuticals | Industry median |
|---|---|---|
| Graham Number | $529.40 | $17.36 |
| Graham Upside | -32.3% | -45.5% |
| Altman Z-Score | 7.13 | 0.10 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Regeneron Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.